Early Alzheimer's

Deaths from Alzheimer's disease rose 142% between 2000 and 2022.1

When the trial criteria for the amyloid antibodies were applied to real patients with mild cognitive impairment, 47% met the inclusion criteria and 8% survived the exclusions.2

142%1
growth in Alzheimer's deaths since 2000
47%2
of real patients met the trial inclusion criteria
8%2
survived the exclusions

Most people with early Alzheimer's cannot take the drugs already approved. The next mechanism has to be one they can.

Please note: Claridge Bio operates in a stealth capacity.

This reaches us directly. We keep your details for correspondence and no other purpose. Privacy.